Citigroup Inc Athenex, Inc. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$0.12 - $0.21 $229 - $401	-1,910 Reduced 99.79%	4 $0
Q3 2022 Nov 10, 2022	SELL	$0.24 - $1.11 $167 - $772	-696 Reduced 26.67%	1,914 $1,000
Q2 2022 Aug 10, 2022	SELL	$0.41 - $0.91 $1,483 - $3,293	-3,619 Reduced 58.1%	2,610 $1,000
Q1 2022 May 12, 2022	SELL	$0.79 - $1.59 $15,084 - $30,359	-19,094 Reduced 75.4%	6,229 $5,000
Q4 2021 Feb 10, 2022	BUY	$1.36 - $2.94 $3,703 - $8,005	2,723 Added 12.05%	25,323 $34,000
Q3 2021 Nov 10, 2021	BUY	$2.97 - $4.84 $67,122 - $109,384	22,600 New	22,600 $68,000

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.